Elite Pharmaceuticals, Inc. (ELTP)

Market Cap	90.04M
Revenue (ttm)	35.46M
Net Income (ttm)	4.40M
Shares Out	1.01B
EPS (ttm)	0.00
PE Ratio	20.91
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,142,900
Open	0.0900
Previous Close	0.0899
Day's Range	0.0861 - 0.0920
52-Week Range	0.0300 - 0.1200
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2023

About ELTP

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 23, 1998
• Employees: 53
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELTP

Financial Performance

In 2022, ELTP's revenue was $34.16 billion, an increase of 105767.55% compared to the previous year's $32.26 million. Earnings were $4.41 billion, an increase of 49459.23%.